Quantcast
Last updated on April 16, 2014 at 12:17 EDT

Latest Upsher-Smith Laboratories Stories

2014-03-24 16:24:14

MAPLE GROVE, Minn., March 24, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), today announced that it has entered into a definitive agreement under which New Jersey-based Vertical Pharmaceuticals, LLC has acquired Upsher-Smith's rights to Divigel(®) (estradiol gel) 0.1%, Nexa(®) Plus Rx Prenatal Vitamin, and Provella(®), a...

2014-03-03 08:33:04

Seizure Clusters Connect(TM) is an Online Community Designed to Provide Support and Resources for Patients and Caregivers MAPLE GROVE, Minn., March 3, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced a new educational program created for patients living with seizure clusters, as well as their families and friends. The initiative--called Seizure Clusters Connect(TM)--uses traditional and social media to offer patients and their caregivers a community for...

2014-01-13 08:30:06

Company Recognizes 2013 Winners of the National Alliance of State Pharmacy Associations' Excellence in Innovation Award MAPLE GROVE, Minn., Jan. 13, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), is pleased to honor the 2013 recipients of the National Alliance of State Pharmacy Associations' (NASPA) Excellence in Innovation Award. Forty-two pharmacists in 41 states were recognized last year. The award is coordinated annually by NASPA and sponsored by Upsher-Smith....

2013-12-10 08:31:19

Impact of Delayed-Dose Administration Results also Announced at the American Epilepsy Society Annual Meeting MAPLE GROVE, Minn., Dec. 10, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the presentation of new Phase 1 data showing that USL255 (extended-release topiramate) may provide a beneficial treatment option for individuals with difficulty swallowing whole capsules or tablets. Additionally, simulations of data from another Phase 1 study...

2013-11-18 08:30:03

Multiple Presentations Highlight Findings from Phase 3 Trial Investigating USL255 for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures MAPLE GROVE, Minn., Nov. 18, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it will present new research from its epilepsy clinical development program for USL255 (extended-release topiramate) during the American Epilepsy Society's (AES) 67(th) Annual Meeting in Washington, DC,...

2013-11-05 08:36:28

Multiple Presentations Highlight Progress of Epilepsy Program MAPLE GROVE, Minn., Nov. 5, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that seven abstracts highlighting results from its Phase 3 (PREVAIL) clinical trial for USL255 (extended-release topiramate) have been accepted for presentation at the American Epilepsy Society's (AES) 67(th) Annual Meeting in Washington, DC, December 6-10, 2013. (Logo:...

2013-09-30 16:25:24

MAPLE GROVE, Minn., Sept. 30, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, today announced that its UK subsidiary, Proximagen Limited, has entered into a preclinical development agreement with Denmark-based H. Lundbeck A/S (Lundbeck) to further its research program related to protein kinase inhibitors. This transaction is part of...

2013-08-29 16:25:25

MAPLE GROVE, Minn., Aug. 29, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced its Morphine Sulfate Extended-Release Capsules, CII will be commercially available on September 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO ) Historically, there have been a limited number of morphine sulfate generics available. Upsher-Smith used its extensive formulation experience to overcome the challenges presented. Upsher-Smith's family of Morphine...

2013-08-16 16:22:14

MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo(TM) (testosterone) gel for topical use CIII. (Logo: http://photos.prnewswire.com/prnh/20130520/NY17281LOGO ) About Upsher-Smith Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company...

2013-08-06 12:24:32

MAPLE GROVE, Minn., Aug. 6, 2013 /PRNewswire/ -- Dara Torres, five-time Olympic swimmer, will return to the training facility in Mission Viejo, California, where she first began her epic career, to kick off AmLactin(®) Alpha-Hydroxy Skin Care's support for U. S. Masters Swimming at their Summer national championship meet. Torres serves as brand ambassador for AmLactin, the #1 moisturizer brand recommended by dermatologists for rough, dry skin(1). (Logo:...